Top

Published in:

Open Access 01-12-2021 | Research

Duration of basic and attenuated-psychotic symptoms in individuals at clinical high risk for psychosis: pattern of symptom onset and effects of duration on functioning and cognition

Authors: Lorna Staines, Ruchika Gajwani, Joachim Gross, Andrew I. Gumley, Stephen M. Lawrie, Matthias Schwannauer, Frauke Schultze-Lutter, Peter J. Uhlhaas

Published in: BMC Psychiatry | Issue 1/2021

Abstract

Introduction

Duration of risk symptoms (DUR) in people at clinical high risk for psychosis (CHR-P) has been related to poorer clinical outcomes, such as reduced functioning, but it is currently unclear how different symptoms emerge as well as their link with cognitive deficits. To address these questions, we examined the duration of basic symptoms (BS) and attenuated psychotic symptoms (APS) in a sample of CHR-P participants to test the hypothesis that BS precede the manifestation of APS. As a secondary objective, we investigated the relationship between DUR, functioning and neuropsychological deficits.

Methods

Data from 134 CHR-P participants were assessed with the Comprehensive Assessment of At-Risk Mental State and the Schizophrenia Proneness Interview, Adult Version. Global, role and social functioning and neurocognition were assessed and compared to a sample of healthy controls (n = 57).

Results

In CHR-P participants who reported both APS and BS, onset of BS and APS was not significantly related. When divided into short and long BS duration (</> 8 years), CHR-P participants with a longer duration of BS showed evidence for an onset of BS preceding APS (n = 8, p = 0.003). However, in the short BS duration group, APS showed evidence of preceding BS (n = 56, p = 0.020). Finally, there were no significant effects of DUR on cognition or functioning measures.

Conclusion

The present findings do not support the view that APS constitute a secondary phenomenon to BS. Moreover, our data could also not confirm that DUR has a significant effect on functioning and cognitive deficits. These findings are discussed in the context of current theories regarding emerging psychosis and the importance of DUR.

Available only for authorised users

Norman RMG, Malla AK. Duration of untreated psychosis: a critical examination of the concept and its importance. Psychol Med. 2001;31(3):381–400. https://doi.org/10.1017/S0033291701003488.CrossRefPubMed

Marshall M, Lewis S, Lockwood A, Drake R, Jones P, Croudace T. Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Arch Gen Psychiatry. 2005;62(9):975–83. https://doi.org/10.1001/archpsyc.62.9.975.CrossRefPubMed

Jonas KG, Fochtmann LJ, Perlman G, Tian Y, Kane JM, Bromet EJ, et al. Lead-Time Bias Confounds Association Between Duration of Untreated Psychosis and Illness Course in Schizophrenia. Am J Psychiatry. 2020; [cited 2020 May 4]; Available from: http://ajp.psychiatryonline.org/doi/abs/10.1176/appi.ajp.2019.19030324.

Rosengard RJ, Malla A, Mustafa S, Iyer SN, Joober R, Bodnar M, et al. Association of pre-onset Subthreshold Psychotic Symptoms with Longitudinal Outcomes during Treatment of a first episode of psychosis. JAMA Psychiatry. 2019;76(1):61–70. https://doi.org/10.1001/jamapsychiatry.2018.2552.CrossRefPubMed

Malla AK, Norman RMG, Manchanda R, Ahmed MR, Scholten D, Harricharan R, et al. One year outcome in first episode psychosis: influence of DUP and other predictors. Schizophr Res. 2002;54(3):231–42. https://doi.org/10.1016/S0920-9964(01)00254-7.CrossRefPubMed

Zhang TH, Xu L, Tang Y, Cui H, Tang X, Wei Y, et al. Relationship between duration of untreated prodromal symptoms and symptomatic and functional recovery. Eur Arch Psychiatry Clin Neurosci. 2018 [cited 2019 Jan 28]; Available from;269(8):871–7. https://doi.org/10.1007/s00406-018-0917-z.CrossRefPubMed

Carrión RE, Demmin D, Auther AM, McLaughlin D, Olsen R, Lencz T, et al. Duration of attenuated positive and negative symptoms in individuals at clinical high risk: associations with risk of conversion to psychosis and functional outcome. J Psychiatr Res. 2016;81:95–101. https://doi.org/10.1016/j.jpsychires.2016.06.021.CrossRefPubMedPubMedCentral

Nelson B, Yuen HP, Lin A, Wood SJ, McGorry PD, Hartmann JA, et al. Further examination of the reducing transition rate in ultra high risk for psychosis samples: the possible role of earlier intervention. Schizophr Res. 2016;174(1–3):43–9. https://doi.org/10.1016/j.schres.2016.04.040.CrossRefPubMed

Zhang TH, Xu L, Tang Y, Cui H, Wei Y, Wang J, et al. Duration of untreated prodromal symptoms in a Chinese sample at a high risk for psychosis: demographic, clinical, and outcome. Psychol Med. 2018;48(8):1274–81. https://doi.org/10.1017/S0033291717002707.CrossRefPubMed

10.

Fusar-Poli P, Meneghelli A, Valmaggia L, Allen P, Galvan F, McGuire P, et al. Duration of untreated prodromal symptoms and 12-month functional outcome of individuals at risk of psychosis. Br J Psychiatry. 2009;194(2):181–2. https://doi.org/10.1192/bjp.bp.107.047951.CrossRefPubMed

11.

Chon M-W, Lee TY, Kim SN, Huh MJ, Park HY, Lee CR, et al. Factors contributing to the duration of untreated prodromal positive symptoms in individuals at ultra-high risk for psychosis. Schizophr Res. 2015;162(1):64–6. https://doi.org/10.1016/j.schres.2015.01.013.CrossRefPubMed

12.

Yung AR, Yung AR, Pan Yuen H, Mcgorry PD, Phillips LJ, Kelly D, et al. Mapping the onset of psychosis: the comprehensive assessment of at-risk mental states. Aust N Z J Psychiatry. 2005;39(11–12):964–71. https://doi.org/10.1080/j.1440-1614.2005.01714.x.CrossRefPubMed

13.

Schultze-Lutter F, Addington J, Ruhrmann S, Klosterkötter J. Schizophrenia Proneness Instrument, Adult version. Roma: Giovanni Fioriti Editore s.r.l; 2007. p. 97.

14.

Fusar-Poli P, Borgwardt S, Bechdolf A, Addington J, Riecher-Rössler A, Schultze-Lutter F, et al. The psychosis high-risk state. JAMA Psychiatry. 2013;70(1):107–20. https://doi.org/10.1001/jamapsychiatry.2013.269.CrossRefPubMedPubMedCentral

15.

Schultze-Lutter F, Klosterkötter J, Ruhrmann S. Improving the clinical prediction of psychosis by combining ultra-high risk criteria and cognitive basic symptoms. Schizophr Res. 2014;154(1):100–6.CrossRef

16.

Ruhrmann S, Schultze-Lutter F, Salokangas RKR, Heinimaa M, Linszen D, Dingemans P, et al. Prediction of psychosis in adolescents and young adults at high risk: results from the prospective European prediction of psychosis study. Arch Gen Psychiatry. 2010;67(3):241–51. https://doi.org/10.1001/archgenpsychiatry.2009.206.CrossRefPubMed

17.

Youn S, Phillips LJ, Amminger GP, Berger G, Chen EYH, de Haan L, et al. Basic symptoms in young people at ultra-high risk of psychosis: association with clinical characteristics and outcomes. Schizophr Res. 2020;216:255–61. https://doi.org/10.1016/j.schres.2019.11.047.CrossRefPubMed

18.

Schultze-Lutter F, Michel C, Ruhrmann S, Schimmelmann BG. Prevalence and clinical relevance of interview-assessed psychosis-risk symptoms in the young adult community. Psychol Med. 2018;48(7):1167–78. https://doi.org/10.1017/S0033291717002586.CrossRefPubMed

19.

Schultze-Lutter F, Debbané M, Theodoridou A, Wood SJ, Raballo A, Michel C, et al. Revisiting the Basic Symptom Concept: Toward Translating Risk Symptoms for Psychosis into Neurobiological Targets. Front Psychiatry. 2016;7 [cited 2019 Aug 22]. Available from: http://journal.frontiersin.org/Article/10.3389/fpsyt.2016.00009/abstract.

20.

Huber G, Gross G. The concept of basic symptoms in schizophrenic and schizoaffective psychoses. Recenti Prog Med. 1989;80(12):646–52.PubMed

21.

Schultze-Lutter F, Ruhrmann S, Berning J, Maier W, Klosterkötter J. Basic symptoms and ultrahigh risk criteria: symptom development in the initial prodromal state. Schizophr Bull. 2010;36(1):182–91. https://doi.org/10.1093/schbul/sbn072.CrossRefPubMed

22.

Schultze-Lutter F, Rahman J, Ruhrmann S, Michel C, Schimmelmann BG, Maier W, et al. Duration of unspecific prodromal and clinical high risk states, and early help-seeking in first-admission psychosis patients. Soc Psychiatry Psychiatr Epidemiol. 2015;50(12):1831–41. https://doi.org/10.1007/s00127-015-1093-3.CrossRefPubMed

23.

Uhlhaas PJ, Gajwani R, Gross J, Gumley AI, Lawrie SM, Schwannauer M. The Youth Mental Health Risk and Resilience Study (YouR-Study). BMC Psychiatry. 2017;17 [cited 2019 Aug 19]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5270216/.

24.

McDonald M, Christoforidou E, Van Rijsbergen N, Gajwani R, Gross J, Gumley AI, et al. Using online screening in the general population to detect participants at clinical high-risk for psychosis. Schizophr Bull. 2019;45(3):600–9. https://doi.org/10.1093/schbul/sby069.CrossRefPubMed

25.

Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(Suppl 20):22–33 quiz 34–57.

26.

Cornblatt BA, Auther AM, Niendam T, Smith CW, Zinberg J, Bearden CE, et al. Preliminary findings for two new measures of social and role functioning in the prodromal phase of schizophrenia. Schizophr Bull. 2007;33(3):688–702. https://doi.org/10.1093/schbul/sbm029.CrossRefPubMedPubMedCentral

27.

Keefe RSE, Goldberg TE, Harvey PD, Gold JM, Poe MP, Coughenour L. The brief assessment of cognition in schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res. 2004;68(2–3):283–97. https://doi.org/10.1016/j.schres.2003.09.011.CrossRefPubMed

28.

Moore TM, Reise SP, Gur RE, Hakonarson H, Gur RC. Psychometric properties of the Penn computerized neurocognitive battery. Neuropsychology. 2015;29(2):235–46. https://doi.org/10.1037/neu0000093.CrossRefPubMed

29.

R Core Team. R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2019. Available from: https://www.R-project.org/

30.

Fusar-Poli P, Rutigliano G, Stahl D, Schmidt A, Ramella-Cravaro V, Hitesh S, et al. Deconstructing pretest risk enrichment to optimize prediction of psychosis in individuals at clinical high risk. JAMA Psychiatry. 2016;73(12):1260–7.CrossRef

31.

Fusar-Poli P, Schultze-Lutter F, Cappucciati M, Rutigliano G, Bonoldi I, Stahl D, et al. The dark side of the moon: meta-analytical impact of recruitment strategies on risk enrichment in the clinical high risk state for psychosis. Schizophr Bull. 2016;42(3):732–43. https://doi.org/10.1093/schbul/sbv162.CrossRefPubMed

32.

Haining K, Matrunola C, Mitchell L, Gajwani R, Gross J, Gumley AI, et al. Neuropsychological deficits in participants at clinical high risk for psychosis recruited from the community: relationships to functioning and clinical symptoms. Psychol Med. 2020;50(1):77–85. https://doi.org/10.1017/S0033291718003975. Epub 2019 Mar 13.

33.

Rapp C, Studerus E, Bugra H, Aston J, Tamagni C, Walter A, et al. Duration of untreated psychosis and cognitive functioning. Schizophr Res. 2013;145(1–3):43–9. https://doi.org/10.1016/j.schres.2012.12.016.CrossRefPubMed

34.

Mills JG, Fusar-Poli P, Morgan C, Azis M, McGuire P. People meeting ultra high risk for psychosis criteria in the community. World Psychiatry. 2017;16(3):322–3. https://doi.org/10.1002/wps.20463.CrossRefPubMedPubMedCentral

Title: Duration of basic and attenuated-psychotic symptoms in individuals at clinical high risk for psychosis: pattern of symptom onset and effects of duration on functioning and cognition
Authors: Lorna Staines
Ruchika Gajwani
Joachim Gross
Andrew I. Gumley
Stephen M. Lawrie
Matthias Schwannauer
Frauke Schultze-Lutter
Peter J. Uhlhaas
Publication date: 01-12-2021
Publisher: BioMed Central
Published in: BMC Psychiatry / Issue 1/2021
Electronic ISSN: 1471-244X
DOI: https://doi.org/10.1186/s12888-021-03267-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Duration of basic and attenuated-psychotic symptoms in individuals at clinical high risk for psychosis: pattern of symptom onset and effects of duration on functioning and cognition

Abstract

Introduction

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2021

Correlates of self-reported history of mental health help-seeking: a cross-sectional study among individuals with symptoms of a mental or substance use disorder initiating care for HIV in Cameroon

Temporal patterns of suicide and circulatory system disease-related mortality are inversely correlated in several countries

Extended network analysis: from psychopathology to chronic illness

Personality traits and their clinical associations in trichotillomania and skin picking disorder

Survival states as indicators of learning performance and biological stress in refugee children: a cross-sectional study with a comparison group

Perceptions, emotional reactions and needs of adolescent psychiatric inpatients during the COVID-19 pandemic: a qualitative analysis of in-depth interviews